

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS & FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO. 807
TO BE ANSWERED ON THE 29TH NOVEMBER 2024

Investigation by NPPA

807. Shri Durai Vaiko:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the National Pharmaceutical Pricing Authority (NPPA) had investigated the claims of the drug manufacturers that the production of certain essential drugs has become “unviable”, before allowing the price rise of essential drugs in October 2024; and
- (b) if so, the details thereof and if not, the reasons therefor?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(SMT. ANUPRIYA PATEL)**

(a) & (b): Yes Sir. The claims of drug manufacturers were scrutinized by an Inter-Ministerial Committee (IMC) comprising of representatives from Central Drugs Standard Control Organisation (CDSCO), Director General of Health Services (DGHS) and National Pharmaceutical Pricing Authority (NPPA) , keeping in view parameters like essentiality of these medicines; period since when they have been under price control; trend of API prices over the last three years; concerns regarding possible shortages, if any; and request(s) received for discontinuation of essential medicines from the manufacturing companies. Based on the detailed scrutiny, increase in the price of only 11 formulations of 8 drugs was approved as against the request received for 77 formulations for such increase.
